Quality-of-life and performance status results from the phase III RAINBOWstudy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma

Annals of Oncology

Volumn 27, Issue 4, 2016, Pages 673-679

  Al Batran, S E ^a   Van Cutsem, E ^b   Oh, S C ^c   Bodoky, G ^d   Shimada, Y ^e   Hironaka, S ^f   Sugimoto, N ^g   Lipatov, O N ^h   Kim, T Y ⁱ   Cunningham, D ^j   Rougier, P ^k   Muro, K ^l   Liepa, A M ^m   Chandrawansa, K ⁿ   Emig, M ^o   Ohtsu, A ^p   Wilke, H ^q  

^a University Cancer Center (UCT) Frankfurt   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Korea University College of Medicine   (South Korea)

^d Szent Laszlo Hospital   (Hungary)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f CHIBA CANCER CENTER   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h Bashkortostan Clinical Oncology Center   (Russian Federation)

ⁱ Seoul National University Hospital   (South Korea)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m ELI LILLY AND COMPANY   (United States)

ⁿ BAYER CORPORATION   (United States)

^o LILLY DEUTSCHLAND GMBH   (Germany)

^p NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^q KLINIKEN ESSEN MITTE   (Germany)

more..

Author keywords

EORTC QLQ C30; EQ 5D; Gastric cancer; GEJ cancer; Quality of life; Ramucirumab

Indexed keywords

PACLITAXEL; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMOTIONALITY; ESOPHAGEAL ADENOCARCINOMA; EUROQOL FIVE DIMENSION HEALTH STATUS QUESTIONNAIRE; FUNCTIONAL STATUS; GASTROESOPHAGEAL ADENOCARCINOMA; GENERAL HEALTH STATUS ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUALITY OF LIFE C30 SCALE; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VISUAL ANALOG SCALE; ADENOCARCINOMA; ADULT; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL JUNCTION; MALE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84964688031     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv625     Document Type: Article

References (19)

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr, accessed on 16 May 2015.
2. Price TJ, Shapiro JD, Segelov E et al. Management of advanced gastric cancer. Expert Rev Gastroenterol Hepatol 2012; 6: 199-209.
3. Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314.
4. Kang JH, Lee SI, Lim DH et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-1518.
5. Ford HER, Marshall A, Bridgewater JA et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an openlabel, phase 3 randomised controlled trial. Lancet Oncol 2014; 15: 78-86.
6. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicenter, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39.
7. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-787.
8. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235.
9. Wilke H, Van Cutsem E, Oh SC et al. RAINBOW: A global, phase III randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy. J Clin Oncol 2014; 32(suppl 3): abstr LBA7.
10. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 2010; 116: 2511-2518.
11. Satoh T, Bang YJ, Gotovkin EA et al. Quality of life in the trastuzumab for gastric cancer trial. Oncologist 2014; 19: 712-719.
12. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
13. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
14. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
15. Fayers PM, Aaronson NK, Bjordal K et al. on behalf of the EORTC Quality of Life Group. EORTC QLQ-C30 Scoring Manual, 3rd Edition. European Organisation for Research and Treatment of Cancer. Brussels: EORTC, 2001. ISBN: 2-9300 64- 22-6.
16. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144. 17. Cox DR, Snell EJ. Analysis of Binary Data, 2nd edition. Chapman & Hall: London, 1989.
17. Cox DR, Snell EJ. Analysis of Binary Data, 2nd edition. Chapman & Hall: London, 1989.
18. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108.
19. Al-Batran SE, Hozaeel W, Tauchert FK et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol 2015; 26: 1244-1248.